Anthracyclines inhibit SARS-CoV-2 infection.

Zhen Wang, Qinghua Pan, Ling Ma, Jianyuan Zhao, Fiona McIntosh, Zhenlong Liu, Shilei Ding, Rongtuan Lin, Shan Cen, Andrés Finzi, Chen Liang

Virus research 2023 Sep

filter terms:

Vaccines and drugs are two effective medical interventions to mitigate SARS-CoV-2 infection. Three SARS-CoV-2 inhibitors, remdesivir, paxlovid, and molnupiravir, have been approved for treating COVID-19 patients, but more are needed, because each drug has its limitation of usage and SARS-CoV-2 constantly develops drug resistance mutations. In addition, SARS-CoV-2 drugs have the potential to be repurposed to inhibit new human coronaviruses, thus help to prepare for future coronavirus outbreaks. We have screened a library of microbial metabolites to discover new SARS-CoV-2 inhibitors. To facilitate this screening effort, we generated a recombinant SARS-CoV-2 Delta variant carrying the nano luciferase as a reporter for measuring viral infection. Six compounds were found to inhibit SARS-CoV-2 at the half maximal inhibitory concentration (IC50) below 1 μM, including the anthracycline drug aclarubicin that markedly reduced viral RNA-dependent RNA polymerase (RdRp)-mediated gene expression, whereas other anthracyclines inhibited SARS-CoV-2 by activating the expression of interferon and antiviral genes. As the most commonly prescribed anti-cancer drugs, anthracyclines hold the promise of becoming new SARS-CoV-2 inhibitors. Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Citation

Zhen Wang, Qinghua Pan, Ling Ma, Jianyuan Zhao, Fiona McIntosh, Zhenlong Liu, Shilei Ding, Rongtuan Lin, Shan Cen, Andrés Finzi, Chen Liang. Anthracyclines inhibit SARS-CoV-2 infection. Virus research. 2023 Sep;334:199164